Companies › ImmuneSensor Therapeutics
3 active drug programs in 11 registered trials: 4 Phase 2, 3 Phase 1, 3 Phase 3, 1 Phase 4; Oncology, Immunology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IMSA101 Intra-tumoral immunotherapy agent | – | Phase 1 | Solid Tumor, Adult; Metastatic Renal Cell Carcinoma ( mRCC) | – |
| IMSB301 Unclear - mechanism not specified in registry text | – | Phase 1 | Type 1 Interferonopathies | – |
| Immune Checkpoint Inhibitor (ICI) Immune checkpoint inhibition | – | Phase 1 | Solid Tumor, Adult; Advanced Biliary Tract Carcinoma; Non-Small Cell Lung Cancer; TNBC - Triple-Negative Breast Cancer … | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06026254 | IMSA101 | Phase 1 | Solid Tumor, Adult | Oncology | Sep 2025 |
| NCT06026254 | Immune Checkpoint Inhibitor (ICI) | Phase 1 | Solid Tumor, Adult | Oncology | Sep 2025 |
| NCT07364513 | IMSB301 | Phase 1 | Type 1 Interferonopathies | Immunology | Jul 2026 |
| NCT05522660 | Immune Checkpoint Inhibitor (ICI) | Phase 3 | Non-Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT07572864 | Immune Checkpoint Inhibitor (ICI) | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | May 2027 |
| NCT06601296 | IMSA101 | Phase 2 | Metastatic Renal Cell Carcinoma ( mRCC) | Oncology | Oct 2027 |
| NCT07759856 | Immune Checkpoint Inhibitor (ICI) | Phase 2 | Small Cell Lung Cancer | Oncology | Aug 2028 |
| NCT06154538 | Immune Checkpoint Inhibitor (ICI) | Phase 2 | Locally Advanced Colorectal Carcinoma | Oncology | Nov 2028 |
| NCT07405086 | Immune Checkpoint Inhibitor (ICI) | Phase 4 | Advanced Biliary Tract Carcinoma | Oncology | Dec 2028 |
| NCT06627712 | Immune Checkpoint Inhibitor (ICI) | Phase 3 | TNBC - Triple-Negative Breast Cancer | Oncology | Nov 2029 |
| NCT07590024 | Immune Checkpoint Inhibitor (ICI) | Phase 3 | Nasopharyngeal Carcinoma (NPC) | Oncology | Dec 2030 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.